

Special Issue

Advanced Research in Melanoma Metastasis

Message from the Guest Editor

Metastatic disease remains the leading cause of mortality in melanoma patients. The mechanisms of melanoma progression, invasion, and metastasis formation have been the focus of extensive studies for decades, as melanoma has been observed as having one of the highest metastatic potentials among human cancers. The metastasis formation of primary tumors is a balance of cellular interactions between the host ('soil') and the tumor ('seed'), characterized by altered crosstalk between cells, a mechanism determined by both the intrinsic properties of the tumor cells and the host response. According to the 'seed and soil' hypothesis, the primary tumor contributes to the preparation of secondary sites for tumor cell invasion and development, known as the pre-metastatic niche. The site of distant metastasis is an important and independent predictor of the survival of melanoma patients with metastatic disease.

This Special Issue focuses on experimental insights into melanoma progression, invasion, and metastasis formation, with particular attention to tumor-host interactions, the pre-metastatic niche, and organ-specific metastatic patterns.

Guest Editor

Dr. Viktória Koroknai

HUN-REN-DE Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/261626

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).